oxiracetam has been researched along with Cognition Disorders in 9 studies
oxiracetam: structure in first source
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effectiveness of Oxiracetam (1600 mg/day) versus placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 9.07 | Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1993) |
| "The effectiveness of oxiracetam (1600 mg/day) vs placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 9.07 | Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1992) |
| "The effectiveness of Oxiracetam (1600 mg/day) versus placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 5.07 | Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1993) |
| "The effectiveness of oxiracetam (1600 mg/day) vs placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 5.07 | Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1992) |
| "Idebenone is a benzoquinone compound which has been investigated in elderly patients with dementia." | 2.39 | Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. ( Benefield, P; Gillis, JC; McTavish, D, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gillis, JC | 1 |
| Benefield, P | 1 |
| McTavish, D | 1 |
| Rozzini, R | 2 |
| Zanetti, O | 2 |
| Bianchetti, A | 2 |
| Green, RC | 1 |
| Goldstein, FC | 1 |
| Auchus, AP | 1 |
| Presley, R | 1 |
| Clark, WS | 1 |
| Van Tuyl, L | 1 |
| Green, J | 1 |
| Hersch, SM | 1 |
| Karp, HR | 1 |
| Villardita, C | 1 |
| Grioli, S | 1 |
| Lomeo, C | 1 |
| Cattaneo, C | 1 |
| Parini, J | 1 |
| Gallai, V | 1 |
| Mazzotta, G | 1 |
| Del Gatto, F | 1 |
| Montesi, S | 1 |
| Mazzetti, A | 1 |
| Dominici, P | 1 |
| Della Monica, A | 1 |
| Gainotti, G | 2 |
| Nocentini, U | 2 |
| Sena, E | 1 |
| Pepeu, G | 1 |
| Vannucchi, MG | 1 |
| Spignoli, G | 1 |
| Benedetti, N | 1 |
| Caltagirone, C | 1 |
1 review available for oxiracetam and Cognition Disorders
| Article | Year |
|---|---|
Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.
Topics: Administration, Oral; Aging; Benzoquinones; Cognition Disorders; Drug Administration Schedule; Human | 1994 |
7 trials available for oxiracetam and Cognition Disorders
| Article | Year |
|---|---|
Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.
Topics: Aged; Ambulatory Care; Cognition Disorders; Dementia; Double-Blind Method; Female; Humans; Male; Neu | 1993 |
Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Dementia; Double-Blind Method; Female; Humans; Male; N | 1992 |
Treatment trial of oxiracetam in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Double-Blind Method; Humans; Neuropsychological Tests; | 1992 |
Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Dementia, Multi-Infarct; Double-Blind Method; Female; | 1992 |
A clinical and neurophysiological trial on nootropic drugs in patients with mental decline.
Topics: Aged; Cognition Disorders; Female; Humans; Male; Mental Disorders; Piracetam; Psychometrics; Psychot | 1991 |
Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?
Topics: Alzheimer Disease; Clinical Trials as Topic; Cognition; Cognition Disorders; Double-Blind Method; Hu | 1989 |
Cognitive improvement in clinical trials with nootropic drugs: when can it be expected and how to clarify its meaning.
Topics: Clinical Trials as Topic; Cognition Disorders; Humans; Psychotropic Drugs; Pyrrolidines; Research De | 1986 |
1 other study available for oxiracetam and Cognition Disorders
| Article | Year |
|---|---|
Cognitive deficits and cholinergic mechanisms in aging brain: investigations on potentially useful drugs.
Topics: Acetylcholine; Aging; Animals; Avoidance Learning; Cerebral Cortex; Cognition Disorders; Corpus Stri | 1988 |